Changing How We Treat Relapsed/Refractory Hairy Cell Leukemia

Most patients with hairy cell leukemia (HCL) will eventually relapse following first-line purine analogue therapy and some will develop purine analogue&ndash refractory disease. Targeted therapies have improved outcomes for these patients with difficult-to-treat disease. Take this opportunity to deepen your understanding of current and evolving best practices for the treatment of patients with relapsed/refractory HCL.

Share

Program Content

Activities

R/R HCL Treatment
Changing How We Treat Relapsed/Refractory Hairy Cell Leukemia
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 24, 2019

Expires: April 22, 2020

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca